New treatment targets for axial spondyloarthritis - Wikidata - awgldk - TriplyDB

New treatment targets for axial spondyloarthritis

New treatment targets for axial spondyloarthritis

http://www.wikidata.org/entity/Q28073999

about

Pain in ankylosing spondylitis: a neuro-immune collaboration.The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?Advances in targeted therapy.Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis.

P2860

Q39374230-961F2602-77AE-49A8-B5B6-EFC3C1F7B6BC Q47159332-34741434-474F-43F1-B6B0-9EFAF2A6D37D Q53707988-2AA6A024-CCBE-4FD1-B139-4AAD27113D6D Q55339808-BBDD2B56-C84D-4566-AA9B-F755F997705D

P2860

New treatment targets for axial spondyloarthritis

http://www.wikidata.org/entity/Q28073999

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

New treatment targets for axial spondyloarthritis

@ast

New treatment targets for axial spondyloarthritis

@en

New treatment targets for axial spondyloarthritis

@nl

type

label

New treatment targets for axial spondyloarthritis

@ast

New treatment targets for axial spondyloarthritis

@en

New treatment targets for axial spondyloarthritis

@nl

prefLabel

New treatment targets for axial spondyloarthritis

@ast

New treatment targets for axial spondyloarthritis

@en

New treatment targets for axial spondyloarthritis

@nl

P1433

Q28073999-CC3FA995-1C26-44EA-955A-99D8786A2B6F

P1476

Q28073999-7D4E171B-F411-4330-9DFD-3F10F210C472

P2093

Q28073999-8BBF21EE-8560-47D2-861F-12FD07ADB612

P2860

Q28073999-0A9D9D69-0C0C-4DFC-BC5A-B542DF9DB436

Q28073999-0B13AD0D-DBF4-4DCF-8DCC-75BDC8181C3A

Q28073999-1DB5CCBF-7233-4BCE-B347-73A7B2030ACF

Q28073999-2ABA63F1-352E-4558-8D93-968C503446E7

Q28073999-33D5999B-3BD4-4628-86D2-031D9C1CDFD0

Q28073999-3530F9C6-ED42-4374-A246-0B270080C7D2

Q28073999-3D3D2521-6EC1-484A-B701-BCD6D501F3D2

Q28073999-4D88983D-D857-49BF-A5F9-014C5327EDC9

Q28073999-51977818-CD94-45CB-B108-11A8211E95B6

Q28073999-55B35904-929B-4169-9C65-E02A8FE80B89

P304

Q28073999-45C06C20-03EF-4EEF-A824-9DA3FBC0F8B1

P31

Q28073999-E780822A-C373-4CE1-BDE3-9BFDF71E0734

P356

Q28073999-60D7ABA3-F59F-495B-B9E4-BA5A0F9A4077

P407

Q28073999-055D9CB8-5D4D-4F57-A7C1-A1BB87958155

P433

Q28073999-0935E223-D7B9-485E-B859-2BDF5A4FF536

P478

Q28073999-B5979DAD-3FBC-4BD8-983D-890D6312E076

P577

Q28073999-1BC79726-527C-4525-B00C-51C803ED6D8B

P698

Q28073999-E04E43C4-014C-4E0B-B184-52F5359E5737

P356

P1433

P1476

New treatment targets for axial spondyloarthritis

@en

P2093

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.

Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

The link between IL-23 and Th17 cell-mediated immune pathologies.

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.

P304

ii38-ii42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEW349

http://www.w3.org/2001/XMLSchema#string

P407

P433

suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27856659

http://www.w3.org/2001/XMLSchema#string